Nova Eye USA Sales Growth Opportunity
Glaucoma Device Product development
Expanding product portfolio leveraging existing IP to expand range of device surgeries covered by
reimbursement codes
ع
ne
Extend product range to cater to the preferences of eye
surgeons treating broader range of patients.
•
iTrack™ Advance product enhancements for "Next Gen"
trabeculotomy product.
Low risk regulatory pathway in USA determined
•
Stable need for trabeculotomy with well-established
reimbursement code.
Glaucoma
surgical devices
segment
Global
market size
2024 (US$
m)(1)
Nova Eye
Product
Canal surgery
devices and stents
$634m
iTrack TM product
suite
GDD segment
(aka "Tube
Shunts")(1)
$108m
MoltenoⓇ
product suite
Severe and complex glaucoma is an underserved
segment.
Molteno3® product enhancements for Molteno "Next Gen"
glaucoma drainage device (GDD) segment.
Low risk regulatory pathway in USA determined
• Stable need for GDD's with well-established reimbursement code
(Progress on Molteno "Next Gen" is subject to cash generated from
sales growth)
Total
$742m
(1) Marketscope 2023 Glaucoma Surgical Device Market Report
nova-eye.com | 17View entire presentation